Intranasal Delivery of Anti-Apoptotic siRNA Complexed with Fas-Signaling Blocking Peptides Attenuates Cellular Apoptosis in Brain Ischemia
Open Access
- 18 February 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (2) , 290
Abstract
Ischemic stroke-induced neuronal cell death leads to the permanent impairment of brain function. The Fas-mediating extrinsic apoptosis pathway and the cytochrome c-mediating intrinsic apoptosis pathway are two major molecular mechanisms contributing to neuronal injury in ischemic stroke. In this study, we employed a Fas-blocking peptide (FBP) coupled with a positively charged nona-arginine peptide (9R) to form a complex with negatively charged siRNA targeting Bax (FBP9R/siBax). This complex is specifically designed to deliver siRNA to Fas-expressing ischemic brain cells. This complex enables the targeted inhibition of Fas-mediating extrinsic apoptosis pathways and cytochrome c-mediating intrinsic apoptosis pathways. Specifically, the FBP targets the Fas/Fas ligand signaling, while siBax targets Bax involved in mitochondria disruption in the intrinsic pathway. The FBP9R carrier system enables the delivery of functional siRNA to hypoxic cells expressing the Fas receptor on their surface—a finding validated through qPCR and confocal microscopy analyses. Through intranasal (IN) administration of FBP9R/siCy5 to middle cerebral artery occlusion (MCAO) ischemic rat models, brain imaging revealed the complex specifically localized to the Fas-expressing infarcted region but did not localize in the non-infarcted region of the brain. A single IN administration of FBP9R/siBax demonstrated a significant reduction in neuronal cell death by effectively inhibiting Fas signaling and preventing the release of cytochrome c. The targeted delivery of FBP9R/siBax represents a promising alternative strategy for the treatment of brain ischemia.Keywords
Funding Information
- Korea Research Foundation (2022R1A2C1011348)
This publication has 78 references indexed in Scilit:
- Chances and challenges in intranasal administration delivery for brain disease treatmentClinical and Translational Discovery, 2023
- Protective Effect of Aliskiren in Experimental Ischemic Stroke: Up-Regulated p-PI3K, p-AKT, Bcl-2 Expression, Attenuated Bax ExpressionNeurochemical Research, 2016
- Intranasal Treatment of Central Nervous System Dysfunction in HumansPharmaceutical Research, 2012
- Nasal drug delivery devices: characteristics and performance in a clinical perspective—a reviewDrug Delivery and Translational Research, 2012
- Apoptotic Mechanisms for Neuronal Cells in Early Brain Injury After Subarachnoid Hemorrhage2011
- Intranasal delivery to the central nervous system: Mechanisms and experimental considerationsJournal of Pharmaceutical Sciences, 2010
- A critical role for Fas/CD‐95 dependent signaling pathways in the pathogenesis of hyperoxia‐induced brain injuryAnnals of Neurology, 2008
- In vitro activation of the corticosteroid ciclesonide in animal nasal mucosal homogenatesBiopharmaceutics & Drug Disposition, 2007
- Direct Nose-to-Brain Transfer of Morphine After Nasal Administration to RatsPharmaceutical Research, 2006
- Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemiaJournal of Neuroscience Research, 2000